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Phosphodiesterases (PDEs) have long been considered as targets for the treatment of
Alzheimer’s disease (AD) and a substantial body of evidence suggests that one sub-
family from the super-family of PDEs, namely PDE4D, has particular signiﬁcance in this
context. This review discusses the role of PDE4 in the orchestration of cAMP response
element binding signaling in AD and outlines the beneﬁts of targeting PDE4D speciﬁcally.
We examine the limited available literature that suggests PDE4 expression does not
change in AD brains together with reports that show PDE4 inhibition as an effective treat-
ment in this age-related neurodegenerative disease. Actually, aging induces changes in
PDE4 expression/activity in an isoform and brain-region speciﬁc manner that proposes
a similar complexity in AD brains. Therefore, a more detailed account of AD-related
alterations in cellular/tissue location and the activation status of PDE4 is required before
novel therapies can be developed to target cAMP signaling in this disease.
Introduction
Phosphodiesterases (PDEs) are the only known enzyme super family that can degrade cyclic nucleo-
tides and their role in cognition was realized in the 1970’s following study of a transgenic ﬂy that was
deﬁcient in learning [1]. The defective gene was identiﬁed as a cyclic-AMP (cAMP) speciﬁc PDE [2]
which we now recognize as PDE4D [3]. Indeed, there is much literature to suggest that aberrant cyclic
AMP (cAMP) signaling is associated with cognitive defects that present in neurodegenerative diseases
including Alzheimer’s disease (AD). Disease-related errors in signal transduction stem from anomal-
ous PDE function, which results in uncoordinated cAMP responses in certain regions of the brain
that can affect memory formation and Aβ production [4].
One family of PDEs that acts to shape cAMP dynamics in neurons and glial cells is PDE4. This
family is subdivided into four subfamilies that are encoded by four genes (A, B, C and D) in mamma-
lian cells (reviewed in [5]). All four genes contain upstream exons that undergo splicing to generate a
variety of PDE4 isoforms (∼25) in conjunction with the use of different promoters, which contain a
unique N-terminal targeting domain, conserved catalytic region and a sub-family speciﬁc C-terminal
region (Figure 1). Further complexity is derived from Upstream Conserved Regions (UCR1 and
UCR2), which act in concert to facilitate enzyme activity changes following PDE4 post-translational
modiﬁcation or dimerization [6].
PDE4s are categorized as long forms (contain UCR1 and UCR2), short forms (contain UCR2) and
super short forms (contain a truncated UCR2) [6] (Figure 1). These regulatory domains allow differ-
ential regulation of PDE4 activity following modiﬁcation by phosphorylation and SUMOylation [7].
PDE4s also exist as dimers and this is relevant to the activity status of the enzyme as the UCR1/UCR2
module of one longform partner can occlude the cAMP binding site of the other in a process called
‘trans-capping’ [8]. Modiﬁcations such as phosphorylation by protein-kinase A (PKA) (in UCR1)
and SUMOylation at the beginning of the catalytic core can lock the PDE4 into the more active
(unoccluded) form, whereas phosphorylation by ERK MAP kinase at the end of the catalytic site can
promote the inactive dimer conformation (active site occluded) [9].
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PDE4 enzymes orchestrate signaling via CREB
Cognitive enhancement in humans is scarcely achieved, however, it has been noted with the PDE4 inhibitor
roﬂumilast in several preclinical trials, establishing proof of concept that PDE4 is a therapeutic target for AD
[10,11]. The potential effects of these inhibitors are attributed to the widely recognized action of cAMP on
memory formation [12,13] and cognition [10,11,14,15]. The mechanisms underpinning these functions relate
to intracellular increases in cerebral cAMP that activate PKA associated with cAMP response element binding
Figure 1. Schematic representation of the four genes of the PDE4 family.
Each gene generates multiple isoform variants with unique N-terminal (Nt) regions encoded by distinct speciﬁc exons (in red).
PDE4 isoforms are classiﬁed upon their regulatory regions UCR1 (dots pattern) and UCR2 (line pattern). All isoforms within a
speciﬁc PDE4 sub-family have identical C-terminal (Ct) regions, except the inactive PDE4A7 that contains a unique 14-residue
Ct end.
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(CREB) protein. CREB activation by PKA is vital for synaptic plasticity and the formation of long-term
memory [16,17], hence there has been a lot of interest in agents that enhance phospho-CREB as possible AD
therapeutics [18,19]. One strategy that has repeatedly and consistently resulted in protective increases in CREB
signaling is the pharmacological inhibition of PDE4 in neurons. Since the 1990s there have been many reports
showing that the active-site targeting, PDE4–speciﬁc inhibitor rolipram can promote CREB signaling in several
brain disease contexts [20–24]. Indeed, it is clear that rolipram reverses learning deﬁcits in rodent models of
AD [25,26] via the CREB mechanism [27,28]. As rolipram has equal afﬁnity for all PDE4 isoforms (an attribute
that results in side effects that has prevented its clinical use), selective inhibitors that are targeted to PDE4 have
been developed to target mainly the PDE4D sub-family of isoforms that are expressed in the hippocampal CA1
region [29,30] and regulate LTP and memory consolidation [31]. One approach has been to develop an
allosteric PDE4D selective compound that works by clamping the enzyme in the ‘occluded’ inhibited state [8].
The allosteric PDE4D compound has been shown to promote cognitive beneﬁt in rodent [8], primate models [32],
humanized mouse models [33,34] and has shown promising results in human trials. Other PDE4D-directed inhibi-
tors have been designed using slight structural differences between the active sites of PDE4 subfamilies to build in
selectivity. The so-called GEBR compounds cross the blood-brain barrier to selectively inhibit PDE4D isoforms,
up-regulate CREB signaling and enhance synaptic plasticity and memory formation in rodent AD models [35–39].
Genetic validation of the role of PDE4D
As already noted, the ﬁrst learning mutation described in fruit ﬂies is a deletion of the PDE4D gene [2].
PDE4D knock-out mice exhibit memory enhancement and augmented hippocampal CREB signaling that can
be mimicked by rolipram treatment or genetic silencing of long-form PDE4D isoforms in wild type mice [40].
RNA interference silencing of longform PDE4Ds can also reverse spatial memory deﬁcits in AD mice that have
Aβ infused into their dentate gyrus [41]. Once again, recovery of low cAMP concentrations and attenuated
CREB signaling was crucial in the gain of function resulting from PDE4D longform ablation. In further
support for the concept that reduced PDE4D activity facilitates cognition and memory formation, genetic
mutations in the human PDE4D gene that cause acrodysostosis [42–44] lead to an activation of PDE4D
longform enzymes (via PKA phosphorylation) [45] that inhibits CREB activity [46] and promotes intellectual
disability [47].
Investigating the mechanism behind depleted cAMP in AD
brains
cAMP is synthesized in neurons by adenylate cyclase (AC) at the membrane and degraded by discretely
positioned PDEs that shape cAMP gradients to allow spatially restricted activation of cAMP effectors [48].
Depletion of brain cAMP concentrations in AD [30,49,50] can therefore be a consequence of reduced
expression/inhibition of AC or overexpression/activation of PDEs (Figure 2). It has been shown that AC can be
inhibited by direct interaction with BACE1 during AD and this promotes reduction in PKA activity and a
down-regulation of CREB activation [51] in an Aβ independent fashion. Moreover, a signiﬁcant reduction in
AC expression and activity is observed in the hippocampus of rats that are chronically infused with Aβ [52,53]
Interestingly, AC activity measurements from post-mortem AD brains showed a similar decrease in the
majority of reports, although contradictory results also exist (reviewed in [50]). For example, one study
reported no AC activity changes in the hippocampal region but a 45% decrease in the frontal cortex. The
ability of AC to respond to G-protein activation remained unaltered in both areas [54]. Another study
described a 50% reduction in basal and stimulated AC activity in post-mortem hippocampi that negatively cor-
related with amyloid plaque formation. The latter study also pinpointed the foci of signal transduction disturb-
ance at the level of the AC catalytic unit [49]. A third report described a signiﬁcant decrease in AC activity in
AD hippocampi and cerebellum [55]. Conversely, the cognitive function improvement in AD transgenic mice
after pituitary adenylate cyclase-activating polypeptide (PACAP) treatment [56] possibly occur via AC, as its
activation by forskolin prevents pathological Aβ inhibition of LTP [56]. Moreover, it has been shown that the
cAMP/PKA pathway can induce production of Aβ in physiological conditions which is instrumental for the
switching of E-LTP to L-LTP through PDE4 inhibition [57]. Therefore, memory deﬁcits in AD could be caused
by a dysregulated cyclic nucleotide signaling that leads to loss of physiological function of Aβ within the brain
including synaptic plasticity [4,58,59].
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Currently, therapeutic treatment with the allosteric PDE4D inhibitors Gebr-7b and Gebr-32a improved
cognition in the APP/PS1 mouse model but was ineffective at reducing Aβ load in the hippocampus [36,39].
Reciprocal results were seen with the use of rolipram, although there was increased phosphorylation of CREB
reversing the deﬁcit present in AD [25]. Interestingly, rolipram led to the clearance of aggregated tau in the
frontal cortex in mouse models of tauopathy [60]. In vitro studies identiﬁed that increasing proteasomal activity
through cAMP/PKA/pCREB resulted in a noted decrease in the levels of ubiquitin conjugates suggesting that
PKA induction is responsible for the enhanced tau clearance [61]. Treatment with rolipram in mice throughout
early disease stage was found to promote proteasomal activity and lead to a reduction in tau accumulation with
subsequent improvement in cognitive defects [61,62]. Thus, the interplay between cAMP, Aβ and tau protein
adds further levels of complexity to an already intricate pathway.
Surprisingly, in the light of the fact that there is a large body of literature unequivocally supporting use of
PDE4 inhibitors as a therapy for memory/cognition enhancement in AD, very little work has been done to
Figure 2. Hypothetical neuronal model of cAMP depletion in AD leading to memory deﬁcits.
Aberrant levels of cAMP can be a consequence of an inactivation of AC by Aβ peptide and BACE1 action or a higher activity of
PDE4 in neurons. The subsequent decline in PKA action leads to a decrease in proteasomal activity associated with tau
accumulation, a down-regulation of CREB signaling and a reduction in Aβ physiological functions.
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proﬁle PDE4 changes during disease progression. Such data is important to enhance our understanding of why
this enzyme family is so pivotal for AD. Of particular importance has been the sub-family PDE4D (reviewed
in [63]). A few studies have attempted to determine whether PDE4 expression is altered in AD brains. In
post mortem, human hippocampi, TaqMan Gene Expression proﬁling of the nine human PDE4D isoforms
(PDE4D1 to 9, inclusive) was evaluated and all were found to be expressed in both healthy and diseased brains
(n = 3 and n = 1, respectively) [30]. However, in the AD hippocampus, expression of the majority of the
isoforms, except for PDE4D1,PDE4D2 and PDE4D4, was dramatically reduced [30]. A different study using
RT-PCR techniques also highlighted no overall change in PDE4D in the temporal cortex of human AD brains
[64], which can be the result of a net effect of all the isoforms or regional differences in expression in the
brain. In conjecture with lack of PDE4D change, both PDE4A and PDE4B mRNA [65] was increased in the
entorhinal cortex. With respect to PDE4 protein, increases in the expression of PDE4A, B and D long forms
(using Western blotting) have been described in mice hippocampi following infusion with Aβ1–42 [66,67]. From
the data that exists there seems to be a discrepancy between the obvious utility of PDE4 inhibitors in AD and
the lack of evidence in human brains that PDE4 level change during disease progression. Crucial to this
conceptual problem is the dearth of information on PDE4 activity changes in AD brains. Amounts of PDE4
mRNA do not always correlate to protein levels and western blotting cannot always evaluate the activity state
of PDE4s, which as stated earlier can be activated and inhibited by point mutations [44], post-translational
modiﬁcation [7,68,69] or by direct association with protein partners [70] or other binding molecules such as
phosphatidic acid [71].
Understanding molecular changes in cAMP signaling that
underpin disease progression is vital to the development of
new treatment regimes
A major caveat of targeting PDE4D for cognitive intervention is the vast diversity of the sub-family isoforms,
each with unique expression patterns, interacting partners and speciﬁc roles within the cell. For example, β1AR
is known to selectively interact with PDE4D8 [72] whereas β2AR has a higher afﬁnity for PDE4D5 [73]. The
β1AR/PDE4D8 complex is only present during the absence of agonist binding allowing for the modulation of
cAMP and subsequently PKA activation in the local vicinity [72]. This control is lost upon ligand binding. The
reverse is true for the β2AR/PDE4D5 complex, which is only present after recruitment of β-arrestin. It is
through this mode of action that β2AR switches between activation of ACs and activation of extracellular
signaling [73]. Then, an incorrect inhibition of either or both isoforms through broad PDE4D inhibition could
lead to signaling dysregulation and undesirable outcomes. Therefore, it is becoming clear that an increase in
the speciﬁcity targeting of PDE4D isoforms will be necessary to improve efﬁcacy while diminishing the
numerous side effects, including emesis and headaches [74], that have plagued the current PDE inhibitors.
Novel complex-speciﬁc PDE4D therapeutics for AD can only be developed by a deep characterization of the
underlying mechanisms of the disease and its progression. Thus, the ideal target candidate would be a PDE
that is pathologically overexpressed in the tissue of interest and responsible for the dysregulated cyclic
nucleotides signaling. An example that supports this view is the differential improvement in working memory
experienced after rolipram treatment in young but not old monkeys [75]. The lack of cognitive enhancement
correlates to a decline in PDE4 expression in the striatum and cortex with aging [76]. In order to avoid the
overstimulation of an already disinhibited cAMP pathway, an exhaustive comparative analysis of cAMP and
PDE4 mRNA, protein and activity from diseased and healthy tissue/cells is required. This methodology has
been previously successful in prostate cancer, where transcripts for PDE4D long forms (and in particular
PDE4D7) are abundant in androgen-sensitive cancer stages but practically disappear in androgen insensitive
cells that are metastatic and drive disease progression [77]. The change in mRNA corresponds to a paucity of
PDE4D7 protein and activity that increases cAMP signaling. These changes are so reproducible that PDE4D7
is now regarded as an important biomarker that can predict pre and post-surgical risk in patients, which allows
better treatment choices to be made [78,79]. In another example, namely autosomal dominant polycystic
kidney disease (ADPKD), a comparable situation arises where chronically elevated cAMP [80] resulting
from activation of AC [81] and reduced levels of PDE4C [82,83] drives cyst formation. Here, a novel PDE4
compound has been developed to suppress excess cAMP by allosterically activating PDE4 longform [84]. In
human and animal models of ADPKD, pharmacological activation of PDE4 puts a brake on cAMP signaling
and profoundly inhibits cyst formation.
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Conclusion
Both cases outlined above illustrate the need for a deeper understanding of the molecular ‘ﬁngerprint’ of cAMP
signaling in AD. The effectiveness of inhibiting the PDE4D sub-family by pharmacological means or genetic
silencing suggests that this enzyme has a unique coordinating role in cognition that is maladapted during AD.
Further analysis of the identity and precise cellular location of single isoforms of PDE4D as well as the activa-
tion state changes that occur during disease should allow novel therapeutic approaches to be developed.
Perspectives
• Importance: PDE4 inhibitors have been shown to be effective in enhancing the cognition and
memory in AD but little is known about changes in PDE4 activity during the disease. This
review looks at mechanistic evidence as to why PDE4 may be a viable target in AD and sug-
gests that more information on the identity, amounts and activation states of PDE4 isoforms
in AD brains may help inﬂuence future treatments.
• Summary of current thinking: Cyclic AMP in the brain has long been thought to promote
memory formation and enhance cognition. Many reports using a variety of techniques have
shown that speciﬁc inhibition of PDE4, and speciﬁcally PDE4D, leads to an increase in cAMP
which in turn promotes the activation of PKA, leading to the phosphorylation of CREB. Active
CREB signaling in the brain is vital for synaptic plasticity and the formation of long-term
memory and hence is a therapeutic target for AD.
• Comment on future directions: The paucity of information surrounding the changes in PDE4
levels and activation state that occur in AD currently do not correlate with the abundance of
evidence suggesting that this enzyme family is a prime target for therapeutic intervention.
Precise information about individual isoforms, their cellular/tissue distribution and activation
state is required to better tailor current PDE4 inhibition strategies for AD.
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